O'Brien S - Search Results

1

Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.

Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. Pollicardo N, et al. Leukemia. 1996 Jan;10(1):27-31. Leukemia. 1996. PMID: 8558933

2

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Estey EH, et al. Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577 Free article.

3

Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia.

del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, el-Naggar A, Deisseroth A. del Giglio A, et al. Blood. 1992 May 15;79(10):2717-20. Blood. 1992. PMID: 1350226 Free article.

4

New drugs in the treatment of chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. Keating MJ, et al. Leukemia. 1992 Nov;6 Suppl 4:140-1. Leukemia. 1992. PMID: 1359203 No abstract available.

5

Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.

Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Kantarjian HM, et al. Am J Med. 1992 Dec;93(6):599-604. doi: 10.1016/0002-9343(92)90191-d. Am J Med. 1992. PMID: 1466355

6

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Kantarjian HM, et al. J Clin Oncol. 1992 May;10(5):772-8. doi: 10.1200/JCO.1992.10.5.772. J Clin Oncol. 1992. PMID: 1569449

7

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

8

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

9

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

10

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,112 results

Search Page

Filters